Trials / Completed
CompletedNCT00004399
Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2,000 (planned)
- Sponsor
- FDA Office of Orphan Products Development · Federal
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
OBJECTIVES: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia.
Detailed description
PROTOCOL OUTLINE: This is a randomized, international, multicenter study. Patients are randomized to receive either nimodipine or magnesium sulfate. Arm I: Patients receive nimodipine by mouth every 4 hours. Treatment is continued until 24 hours post-partum. Arm II: Patients receive a loading dose of magnesium sulfate IV for 20 minutes, followed by continuous infusion of magnesium sulfate. Treatment is continued until 24 hours post-partum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | magnesium sulfate | |
| DRUG | nimodipine |
Timeline
- Start date
- 1995-09-01
- Completion
- 2000-08-01
- First posted
- 1999-10-19
- Last updated
- 2015-03-25
Source: ClinicalTrials.gov record NCT00004399. Inclusion in this directory is not an endorsement.